AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$CTSO

Chan Phillip P. purchased $23K of CTSO

Chan Phillip P. (Chief Executive Officer) purchased 3,774 shares of Cytosorbents Corp (CTSO) at $6.00 on 2026-09-15.

Original reporting
SEC EDGAR · Chan Phillip P.
Published Sep 16, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CTSO
Neutral
high confidence
Mentioned
$CTSO
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CTSONeutralLow
01

Why it matters

The disclosed purchase adds a small amount of insider confidence but is unlikely to affect market pricing.

02

Market read

A routine insider purchase with limited trading relevance.

03

What to watch

Potential upcoming clinical data or partnership announcements could give the purchase more relevance.

Relevance 4/10Novelty 3/10Timing: post-market 2026-09-15

Background

Form 4 filings disclose insider transactions and are primary sources of new information.

Company-level read

Ticker impact

$CTSONeutralHigh confidence
Context

CEO Chan Phillip P. bought 3,774 shares at $6 each, total $22,644, increasing his stake to 100,996 shares.

Expected impact

Minimal to no price impact in the short term.

Evidence & confidence

Insider purchases under $25k are typically viewed as routine and do not generate significant market reaction.

Market effects

Sector

No material effect on the biotech/medical device sector.

Regional

Limited to US micro‑cap investors.

Global

None

Counterpoint

What could challenge this read

If the CEO is signaling confidence, a modest rally could follow.

Key entities

  • company
    Cytosorbents Corp

    US‑listed biotech company (ticker CTSO).

  • person
    Chan Phillip P.

    Chief Executive Officer of Cytosorbents Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CTSO insider trading history →

Related articles

AUG 14
$CTSOMed

Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

Cytosorbents (CTSO) reported Q2 2026 revenue of $9.6 million, flat vs. the prior year and up 9% sequentially, with 73% gross margin. Adjusted EBITDA loss was $1.6 million, a 38% improvement. Net loss was $4.4 million. Management discussed FDA strategy for DrugSorb-ATR after a de novo denial, and progress on HemoDefend-BGA. Cash was $5.9 million.

fool.com6 min
AUG 6
$CTSOMed

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of…

Cytosorbents Corp (CTSO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update Highlighting Four Independent Drivers of Shareholder Value PRINCETON, N.J., August 6, 2026 — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatme

SEC EDGAR 8-K6 min
JUN 2
$CTSOMedAI 9/10

Cytosorbents (CTSO) Q1 2026 Earnings Transcript

Cytosorbents (CTSO) reported Q1 2026 revenue of $8.9 million, up 2% YoY, with direct international markets (excluding Germany) up 13% while Germany declined. Gross margin fell to 69% from 71%. Adjusted EBITDA loss narrowed to $2.2 million (vs. $2.7 million), as operating expenses dropped to $9.2 million. Net loss was $5.1 million ($0.08/share). FDA said DrugSorb-ATR needs additional non-clinical data and real-world evidence for a de novo submission, likely pushing timing to late 2026/early 2027.

fool.com6 min